Other Events ·
On August 18, 2026, UroGen Pharma Ltd. entered into an Option and Research License Agreement with IntraGel…
URGNUroGen Pharma Ltd.
On August 18, 2026, UroGen Pharma Ltd. entered into an Option and Research License Agreement with IntraGel Therapeutics, Ltd., securing an exclusive worldwide option to license the TumoCure product and SRGel platform for advanced head and neck cancer treatment. The company also signed a Securities Purchase Agreement to invest up to $7,000,000 in IntraGel's equity securities. UroGen Pharma Ltd. operates in the biopharmaceutical industry, focusing on the development of therapies for urological diseases.